Last reviewed · How we verify
Copper Cu-64-DOTA-alendronate
At a glance
| Generic name | Copper Cu-64-DOTA-alendronate |
|---|---|
| Also known as | 64Cu-DOTA-alendronate; [64Cu]-DOTA-alendronate |
| Sponsor | City of Hope Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- 64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Copper Cu-64-DOTA-alendronate CI brief — competitive landscape report
- Copper Cu-64-DOTA-alendronate updates RSS · CI watch RSS
- City of Hope Medical Center portfolio CI